Drug Trial Radar · NCT05145127
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
245
Planned (sponsor's estimate)
Start
Nov 17, 2021
Primary completion
Jul 31, 2030
Study completion Jul 31, 2030
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 1 year, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005 and from the Phase 3 Study B7841008. Study B7841005: approximately 145 adolescent and adult participants 12 to \<75 years of age with severe hemophilia A or moderately severe to severe hemophilia B (defined as FVIII activity \<1% or FIX activity ≤2%, respectively) with or without inhibitors are expected to be enrolled in Study B7841005 during which they will receive prophylaxis (defined as treatment by SC injection of marstacimab). Study B7841008: this is an ongoing Phase 3, open-label study in pediatric participants \<18 years of age with severe hemophilia A (FVIII Coagulation Factor Activity \<1%) or moderately severe to severe hemophilia B (FIX Coagulation Factor Activity ≤2%). A sequential approach will be used in enrolling at least 100 pediatric participants, at least 20 of which will be aged ≥12 to \<18 years and at least 80 participants will be aged ≥1 to \<12 years. At the start of study B7841008, the dosing and data available in adolescent and adult participants in Study B7841005 supported the initiation of B7841008 study in participants aged ≥12 to \<18 years. Subsequently, additional safety and efficacy data from adolescent participants in Study B7841005 became available for benefit/risk assessment in support of dosing participants aged ≥6 to \<12 years. Based on the positive benefit/risk assessment conducted by both internal Pfizer review and eDMC review, dosing of the ≥6 to \<12 years age group was initiated in June 2023 in B7841008 Study. Data from participants ≥6 years from B7841008 Study and Study B7841005 will support the dosing of participants aged ≥1 to \<6 years. All participants will be provided the prefilled pen (PFP) for administration of marstacimab in the study. Use of the prefilled syringe (PFS) will be permitted at the investigator's discretion for those participants who have difficulty with administration of the PFP. Additionally, participants will be provided the PFS for use in this study in countries where the PFS is anticipated to be the only presentation available commercially. An optional, open-label, single arm, substudy using the PFP was completed in the first 23 participants rolled over from Study B7841005 who agreed to participate in the substudy.
Conditions
- Hemophilia A
- Hemophilia B
Interventions
PF-06741086Drug
For participants aged ≥12 years 300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria. For participants aged ≥6 to \<12 years is marstacimab 150 mg SC for initial loading dose followed by 75 mg SC QW. 150 mg sc qw is prescribed for participants who meet dose escalation criteria.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subject reporting Adverse EventsTime frame: Baseline up to 7 years
- Number of subjects reporting Serious Adverse EventsTime frame: Baseline up to 7 years
- Incidence and severity of thrombotic eventsTime frame: Baseline up to 7 years
- Incidence and severity of thrombotic microangiopathyTime frame: Baseline up to 7 years
- Number of subjects reporting Disseminated intravascular coagulalopathy/consumption coagulopathyTime frame: Baseline up to 7 years
- Incidence of clinically significant persistent NAb against marstacimabTime frame: Baseline up to 7 years
- Incidence and severity of injection site reactionTime frame: Baseline up to 7 years
- Clinically significant changes in vital signs from baselineTime frame: Baseline up to 7 years
- Incidence of clinically significant laboratory value abnormalitiesTime frame: Baseline up to 7 years
- Incidence of severe hypersensitivity and anaphylactic reactionsTime frame: Baseline up to 7 years
Locations
78 sites in 24 countries. Site status is shown where the registry gives one.
University of Iowa
Iowa City, Iowa · Active not recruiting
Northwell Health HTC
New Hyde Park, New York · Recruiting
The Feinstein Institutes for Medical Research
Philadelphia, Pennsylvania · Recruiting
Washington Institute for Coagulation d/b/a WACBD
Seattle, Washington · Recruiting
Arbesu Hematología
Mendoza, Argentina · Recruiting
Royal Children's Hospital
Melbourne, Victoria, Australia · Recruiting
HEMOES
Vitória, Espírito Santo, Brazil · Recruiting
Stollery Children's Hospital
Edmonton, Alberta, Canada · Recruiting
Hamilton Health Sciences - McMaster University Medical Centre
Hamilton, Ontario, Canada · Recruiting
Hamilton Health Sciences - McMaster University Medical Centre
Hamilton, Ontario, Canada · Recruiting
Beijing Children's Hospital, Capital Medical University
Beijing, China · Recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China · Recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Recruiting
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China · Recruiting
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China · Recruiting
Institute of hematology&blood disease hospital
Tianjin, Tianjin Municipality, China · Recruiting
Klinicki bolnicki centar Zagreb
Zagreb, Croatia · Recruiting
Aarhus Universitetshospital, Skejby
Aarhus, Central Jutland, Denmark · Recruiting
Hôpital Universitaire Necker Enfants Malades
Paris, France · Recruiting
The University of Hong Kong (HKU)-Queen Mary Hospital (QMH)
Hong Kong, Hong Kong · Recruiting
Prince of Wales Hospital
Hong Kong, Hong Kong · Recruiting
Queen Mary Hospital
Hong Kong, Hong Kong · Recruiting
The Chinese University of Hong Kong
Ma Liu Shui, Hong Kong · Recruiting
Nirmal Hospital Pvt Ltd.
Surat, Gjuarat, India · Recruiting
K.J Somaiya Hospital & Research Centre, Somaiya Ayurvihar Complex
Mumbai, Maharashtra, India · Recruiting
Sahyadri Super Speciality Hospital
Pune, Maharashtra, India · Recruiting
Nil Ratan Sircar Medical College and Hospital
Kolkata, West Bengal, India · Recruiting
Sheba Medical Center
Ramat Gan, Central District, Israel · Recruiting
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Italy · Recruiting
IRCCS Istituto Giannina Gaslini
Genoa, Liguria, Italy · Recruiting
Istituto Clinico Humanitas
Rozzano, Milano, Italy · Recruiting
AOU Policlinico Umberto I
Roma, RM, Italy · Recruiting
Hiroshima University Hospital
Hiroshima, Japan · Active not recruiting
Saga University Hospital
Saga, Japan · Recruiting
Nagoya University Hospital - Transfusion Medicine
Nagoya, Aichi-ken, Japan · Active not recruiting
Nagano Children's Hospital
Azumino, Nagano, Japan · Recruiting
Nara Medical University Hospital
Kashihara, Nara, Japan · Recruiting
Saitama Medical University Hospital
Lruma-gun, Saitama, Japan · Recruiting
Saitama Children's Medical Center
Saitama-shi, Saitama, Japan · Recruiting
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.